Approval · Notice of Compliance 15223 · 2014
ABILIFY MAINTENA: Notice of Compliance 15223
Issued February 10, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15223
- Date
- February 10, 2014
- Company
- Otsuka Pharmaceutical Co LtdChiyoda-Ku Tokyo, --, Japan
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Antipsychotic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABILIFY MAINTENA | 02420864 | Marketed |
| ABILIFY MAINTENA | 02420872 | Marketed |
Medicinal ingredients
- ARIPIPRAZOLE 300 MG per VIAL
- ARIPIPRAZOLE 400 MG per VIAL